MELILLO, Giovanni,BALLAS, Marc,DOVEDI, Simon,STEWART, Ross
申请号：
AU2018412532
公开号：
AU2018412532A1
申请日:
2018.03.08
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
Disclosed are methods for treating late stage (e.g., clinical stage III or IV), unresectable non-small-cell lung cancer (NSCLC) with an antibody that inhibits PD1/PD-L1 activity in a patient identified as having not progressed following definitive chemoradiation therapy.
